Baseline characteristics for BRAFV600E-mutant patients with ATC (n=30)
| Baseline Characteristic | Summary Statistic |
|---|---|
| Age at surgery, mean (standard deviation) | 66.5 (9.0) |
| Sex, frequency (percent) | |
| Men | 17 (56.7%) |
| Women | 13 (43.3%) |
| AJCC Eighth Edition stage,30 frequency (percent) | |
| IVB | 15 (50.0%) |
| IVC | 15 (50.0%) |
| Days of neoadjuvant BRAF/MEK inhibitor therapy, median (IQR) | 103.5 (79.8–196.5) |
| Immunotherapy before and/or after surgery, frequency (percent) | 28 (93.3%) |
| Pembrolizumab | 25 (89.3%) |
| Atezolizumab | 3 (10.7%) |
| Surgically sampled lesions with known pathology | |
| Low risk (no tumor, PTC) | 57 (60.6%) |
| High risk (PDTC, ATC) | 37 (39.4%) |
Note:—AJCC indicates American Joint Committee on Cancer Classification.